1. Search Result
Search Result
Results for "

nervous

" in MCE Product Catalog:

208

Inhibitors & Agonists

11

Screening Libraries

2

Dye Reagents

31

Peptides

2

Inhibitory Antibodies

31

Natural
Products

1

Recombinant Proteins

35

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-14550A
    PDE10-IN-5

    Phosphodiesterase (PDE) Others
    PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders.
  • HY-N2321
    Salsolinol-1-carboxylic acid

    Others Neurological Disease
    Salsolinol-1-carboxylic acid is an endogenous alkaloid in the central nervous system (CNS).
  • HY-115139
    Fenadiazole

    Others Neurological Disease
    Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess.
  • HY-N3193
    Neritaloside

    Others Neurological Disease
    Neritaloside could be isolated from nerium oleander. Neritaloside has central nervous system (CNS) depressant effect[2.
  • HY-136560
    6-Azathymine acid

    Drug Metabolite Others
    6-Azathymine acid is a metabolite of Pymetrozine. Pymetrozine is active against plant-sucking insects, such as aphids and whiteflies in vegetables, cotton, field crops and fruits and affects the nervous regulation of feeding behavior.
  • HY-144330
    EZH2-IN-12

    Histone Methyltransferase Cancer
    EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2. EZH2-IN-12 has the potential for the research of central nervous system malignancies.
  • HY-122367
    Neoxaline

    Others Neurological Disease
    Neoxaline is an alkaloid produced by Aspergillus japonicus. Neoxaline does not possess antimicrobial activities, but weakly stimulates the central nervous system.
  • HY-P1438
    Neuropeptide S(Rat)

    Neuropeptide Y Receptor Neurological Disease
    Neuropeptide S (Rat) is an endogenous ligand of a previously orphan G-protein-coupled receptor now named NPS receptor. Neuropeptide S (Rat) can be used for the research of nervous system disease.
  • HY-17034B
    Medetomidine hydrochloride

    MPV785

    Adrenergic Receptor Neurological Disease Endocrinology
    Medetomidine (hydrochloride) is a potent, selective, and specific α2-adrenoceptor agonist in both the peripheral and central nervous systems. Medetomidine hydrochloride can induce sedation, analgesia, anxiolysis, and muscle relaxation in a variety of species.
  • HY-B1067A
    Antazoline

    Phenazoline

    Histamine Receptor Neurological Disease
    Antazoline (Phenazoline) is an H1 receptor
    antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect.
  • HY-145959
    AMPA receptor antagonist-3

    iGluR Neurological Disease
    AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders.
  • HY-106901A
    Asoxime dichloride

    HI-6

    nAChR Neurological Disease
    Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system.
  • HY-B0933
    Gadoteridol

    SQ-32692; Gd-HP-DO3A

    Others Neurological Disease
    Gadoteridol is a gadolinium-based magnetic resonance imaging (MRI) contrast agent, used in the imaging of the central nervous system.
  • HY-B0933A
    Gadoteridol pentahydrate

    SQ-32692 pentahydrate; Gd-HP-DO3A pentahydrate

    Others Neurological Disease
    Gadoteridol pentahydrate is a gadolinium-based magnetic resonance imaging (MRI) contrast agent, used in the imaging of the central nervous system.
  • HY-124775
    (S)-C33

    Phosphodiesterase (PDE) Neurological Disease
    (S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC50 of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research.
  • HY-147399
    5-HT7 agonist 2

    5-HT Receptor Neurological Disease
    5-HT7 agonist 2 is a potent 5-HT7 receptor agonist with an IC50 value of 28.7 nM. 5-HT7 agonist 2 can be used for research of central nervous system (CNS) disorders.
  • HY-N2085
    L-Perillaldehyde

    (S)-(-)-Perillaldehyde; (S)-Perillaldehyde

    Others Neurological Disease
    L-Perillaldehyde is a major component in the essential oil containing in Perillae Herba. Inhalation of L-Perillaldehyde shows antidepressant-like activity through the olfactory nervous function.
  • HY-109149
    Lomardexamfetamine

    KP 106

    Others Neurological Disease
    Lomardexamfetamine (KP 106) is an orally active central nervous system stimulant composed of d-amphetamine and a ligand. Lomardexamfetamine can be used for the research of attention-deficit hyperactivity disorder.
  • HY-P1483
    Urotensin II, mouse

    Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse is a potent vasoconstrictor. Urotensin II, mouse plays a physiological role in the central nervous system.
  • HY-P1483B
    Urotensin II, mouse acetate

    Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.
  • HY-15708
    LY2795050

    Opioid Receptor Neurological Disease
    LY2795050 is a short-acting selective κκ-opioid receptor (KOR) antagonist. LY2795050 has high affinity for the KOR with Ki value of 0.72 nM. LY2795050 can be used for the research of central nervous system dysfunction.
  • HY-P1483A
    Urotensin II, mouse TFA

    Urotensin Receptor Neurological Disease Cardiovascular Disease
    Urotensin II, mouse TFA is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse TFA is a potent vasoconstrictor. Urotensin II, mouse TFA plays a physiological role in the central nervous system.
  • HY-107523A
    WAY-213613 hydrochloride

    EAAT2 Neurological Disease
    WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system.
  • HY-107523
    WAY-213613

    EAAT2 Neurological Disease
    WAY-213613 is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC50 value of 85 nM. WAY-213613 can be used for the research of central nervous system
  • HY-D0953
    Direct Blue 86

    Solvent Blue 38

    Others Neurological Disease
    Direct Blue 86 (Solvent Blue 38) is a myelin-sheath stain, commonly utilized in microscopy to detect demyelination in the central nervous system. Direct Blue 86 also is a dye with various applications including as a commercial dye in the printing of cotton and mucilage glue fabrics.
  • HY-145778
    AGI-41998

    Somatostatin Receptor Neurological Disease
    AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease.
  • HY-14612
    CPPHA

    mGluR Neurological Disease
    CPPHA is potent and selective positive allosteric modulator (PAM) of the mGluR5 and mGluR1 (metabotropic glutamate receptor). CPPHA can potentiate responses of mGluR5 and mGluR1 to activation of these receptors. CPPHA is developed for the research of central nervous system disorders.
  • HY-111263
    NIAD-4

    Amyloid-β Others Neurological Disease
    NIAD-4 is a fluorophore for optical imaging of amyloid-β () in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM.
  • HY-145777
    AGI-43192

    Somatostatin Receptor Cancer Neurological Disease
    AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease.
  • HY-P1558A
    ACTH (11-24) (acetate)

    Adrenocorticotropic Hormone (11-24) (acetate)

    Melanocortin Receptor Neurological Disease
    ACTH (11-24) (acetate) is an adrenocorticotropic hormone (ACTH) receptor antagonist. ACTH (11-24) is a fragment of adrenocorticotropic and induces cortisol release. ACTH (11-24) can be used for the research of central nervous system.
  • HY-P1558
    ACTH (11-24)

    Adrenocorticotropic Hormone (11-24)

    Melanocortin Receptor Neurological Disease
    ACTH (11-24) is an adrenocorticotropic hormone (ACTH) receptor antagonist. ACTH (11-24) is a fragment of adrenocorticotropic and induces cortisol release. ACTH (11-24) can be used for the research of central nervous system.
  • HY-15722
    SB-222200

    Neurokinin Receptor Neurological Disease Endocrinology
    SB-222200 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant NK-3 receptor antagonist. SB-222200 is developed for central nervous system (CNS) disorders.
  • HY-145607
    Zagociguat

    Guanylate Cyclase Cardiovascular Disease
    Zagociguat is the stimulator of soluble guanylate cyclase. Zagociguat increases nitric oxide (NO) signaling leading to an increase in cyclic guanosine monophosphate production. Zagociguat has the potential for the research of noncentral nervous system (CNS) disorders.
  • HY-12560A
    PNU-282987

    nAChR 5-HT Receptor Neurological Disease
    PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems.
  • HY-N0301
    Thiocolchicoside

    GABA Receptor Inflammation/Immunology Neurological Disease
    Thiocolchicoside is a competitive γ-aminobutyric acid type A (GABAA) receptor antagonist and glycine receptor agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside. Thiocolchicoside is a muscle relaxant and has anti-inflammatory, and analgesic properties.
  • HY-132308
    DYRK1-IN-1

    DYRK Neurological Disease
    DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 inhibits DYRK1A phosphorylation activity with an IC50 value of 220 nM. DYRK1-IN-1 can be used for the research of central nervous system penetrant DYRK1A chemical probe.
  • HY-12560
    PNU-282987 free base

    nAChR 5-HT Receptor Neurological Disease
    PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems.
  • HY-118689
    RA-2

    Potassium Channel Inflammation/Immunology Neurological Disease Cardiovascular Disease
    RA-2 is a negative-gating modulator of KCa2/3 channels with an IC50 of 17 nM. RA-2 inhibits bradykinin-induced endothelium-derived hyperpolarization (EDH)-type relaxation in U46619-precontracted rings. RA-2 can help to define the physiologic and pathomechanistic roles of KCa2/3 in the vasculature, central nervous system, and during inflammation.
  • HY-103111
    MMPIP hydrochloride

    mGluR Neurological Disease
    MMPIP hydrochloride is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP hydrochloride acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP hydrochloride alleviates pain and normalizes affective and cognitive behavior in neuropathic mice.
  • HY-107503
    MMPIP

    mGluR Neurological Disease
    MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice.
  • HY-110053
    Tandospirone hydrochloride

    SM-3997 hydrochloride

    5-HT Receptor Neurological Disease
    Tandospirone (SM-3997) hydrochloride is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone hydrochloride has anxiolytic and antidepressant activities. Tandospirone hydrochloride can be used for the research of the central nervous system disorders and the underlying mechanisms.
  • HY-14558
    Tandospirone

    SM-3997

    5-HT Receptor Neurological Disease
    Tandospirone (SM-3997) is a potent and selective 5-HT1A receptor partial agonist, with a Ki of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms.
  • HY-103190
    MRS1220

    Adenosine Receptor Cancer Neurological Disease
    MRS1220, a highly potent and selective human A3 adenosine receptor (hA3AR) antagonist with a Ki of 0.59 nM, has therapeutic potential for the research of diseases of the central nervous system. MRS1220 reduces glioblastoma tumor size and blood vessel formation in vivo.
  • HY-100743
    DL-AP4

    2-Amino-4-phosphonobutyric acid

    Others Metabolic Disease Neurological Disease
    DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system.
  • HY-N0067
    γ-Aminobutyric acid

    4-Aminobutyric acid

    GABA Receptor Endogenous Metabolite Neurological Disease
    γ-Aminobutyric acid (4-Aminobutyric acid) is a major inhibitory neurotransmitter in the adult mammalian brain, binding to the ionotropic GABA receptors (GABAA receptors) and metabotropic receptors (GABAB receptors. γ-Aminobutyric acid shows calming effect by blocking specific signals of central nervous system.
  • HY-144874
    AZ3391

    PARP Cancer Neurological Disease
    AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23).
  • HY-P1944
    Apelin-13

    Apelin Receptor (APJ) Metabolic Disease Cardiovascular Disease
    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome.
  • HY-W011051
    2-Arachidonoylglycerol

    Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-B1229
    Isovaleramide

    3-Methylbutanamide

    Others Neurological Disease
    Isovaleramide is an active principle on central nervous system from Valeriana pavonii, as an anticonvulsant.
  • HY-B1236
    Sulfacarbamide

    Others Cardiovascular Disease
    Sulfacarbamide is a blood sugar-lowering drug, also acting on the vegetative nervous system.
  • HY-B0740
    Cyclobenzaprine hydrochloride

    MK130 hydrochloride

    5-HT Receptor Neurological Disease
    Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant.
  • HY-W294348
    Prenderol

    2,2-Diethyl-1,3-propanediol

    Others Neurological Disease
    Prenderol is a potent central-nervous-system depressant. Prenderol has anticonvulsant activity.
  • HY-16173
    Mipicoledine

    DM-CHOC-PEN

    DNA Alkylator/Crosslinker Cancer Neurological Disease
    Mipicoledine is a potential neuro-alkylating agent for study of glioblastoma and metastatic cancers involving the central nervous system.
  • HY-B0827
    Dinotefuran

    MTI-446

    Parasite nAChR Infection
    Dinotefuran is an insecticide of the neonicotinoid class, its mechanism of action involves disruption of the insect's nervous system by inhibiting nicotinic acetylcholine receptors.
  • HY-101022
    CXCR2-IN-1

    CXCR Inflammation/Immunology Endocrinology
    CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonist with a pIC50 of 9.3.
  • HY-N2327
    Oleamide

    Endogenous Metabolite Others
    Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.
  • HY-121404A
    Muscarine chloride

    (+)-Muscarine chloride

    mAChR Neurological Disease
    Muscarine ((+)-Muscarine) chloride is a toxin that can stimulate the parasympathetic nervous system. Muscarine is a prototype muscarinic acetylcholine receptor agonist.
  • HY-U00382
    Substance P Receptor Antagonist 1

    Neurokinin Receptor Inflammation/Immunology Neurological Disease
    Substance P Receptor Antagonist 1 has the potential function in central nervous system disorders, respiratory, inflammatory diseases and gastrointestinal disorders.
  • HY-N0229
    L-Alanine

    L-2-Aminopropionic acid

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-15204
    Tonabersat

    SB-220453

    Gap Junction Protein Inflammation/Immunology Neurological Disease
    Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system.
  • HY-B1326
    Bemegride

    3-Ethyl-3-methylglutarimide; Bemegrid

    GABA Receptor Neurological Disease
    Bemegride (3-Ethyl-3-methylglutarimide) is a central nervous system stimulant and antidote for barbiturate poisoning.
  • HY-B1007
    Butacaine

    Others Neurological Disease
    Butacaine is a reversible nerve conduction blocker. Butacaine acts on the nervous system and nerve fibers, can cause both sensory and motor paralysis.
  • HY-145295
    Flupyradifurone

    nAChR Infection
    Flupyradifurone is a systemic nAChR agonist that interferes with signal transduction in the central nervous system of sucking pests. Flupyradifurone can be used as a butenolide insecticide.
  • HY-107654
    Muscarine iodide

    (+)-Muscarine iodide

    mAChR Neurological Disease
    Muscarine ((+)-Muscarine) iodide is a toxin that can stimulate the parasympathetic nervous system. Muscarine iodide is a prototype muscarinic acetylcholine receptor agonist.
  • HY-B0315
    Vitamin B12

    Cyanocobalamin

    Endogenous Metabolite Metabolic Disease
    Vitamin B12 is a vitamin. Vitamin B12 plays a key role in the normal functioning of the brain and nervous system, and for the formation of blood.
  • HY-N5121
    Calycanthine

    Others Neurological Disease
    Calycanthine, the principal alkaloid of the order Calycanthaceae, has been isolated from a species of the genus Psychotria, and is a central nervous system toxin, causing convulsions.
  • HY-W011051S1
    2-Arachidonoylglycerol-d5

    Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d5 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-W011051S
    2-Arachidonoylglycerol-d8

    Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d8 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-14758
    Adipiplon

    NG2-73

    GABA Receptor Neurological Disease
    Adipiplon (NG2-73) is a selective GABAA receptor positive allosteric modulator. Adipiplon is particularly useful in the treatment of a variety of central nervous system (CNS) disorders.
  • HY-B1111
    Amitraz

    BTS-27419

    Adrenergic Receptor Monoamine Oxidase Parasite Infection Endocrinology
    Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.
  • HY-143546
    RET-IN-9

    RET Cancer
    RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29).
  • HY-139680
    Dopamine D3 receptor antagonist-1

    Dopamine Receptor Neurological Disease
    Dopamine D3 receptor antagonist-1 is a dopamine D3 receptor-selective or multitarget bitopic ligand (Ki = 1.58 nM) potentially useful for central nervous system disorders.
  • HY-139681
    Dopamine D3 receptor antagonist-2

    Dopamine Receptor Neurological Disease
    Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective (Ki = 2.16 nM) or multitarget bitopic ligand potentially useful for central nervous system disorders.
  • HY-W017389
    Xanthine

    Endogenous Metabolite Inflammation/Immunology
    Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation.
  • HY-139580
    Plazinemdor

    iGluR Neurological Disease
    Plazinemdor is a N-methyl-D-aspartate(NMDA) receptor positive allosteric modulator. Plazinemdor can be uses in the research of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system..
  • HY-W011051S2
    2-Arachidonoylglycerol-d11

    Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    2-Arachidonoylglycerol-d11 is deuterium labeled 2-Arachidonoylglycerol.2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-106147
    Frakefamide

    Opioid Receptor Neurological Disease
    Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.
  • HY-69019
    7-Nitroindazole

    NO Synthase Neurological Disease Cardiovascular Disease
    7-Nitroindazole is a selective nNOS inhibitor with antinociceptive and cardiovascular effects. 7-Nitroindazole is a useful tool to evaluate the biological roles of nitric oxide in the central nervous system.
  • HY-B0740S
    Cyclobenzaprine-d3 hydrochloride

    MK130-d3 hydrochloride

    5-HT Receptor Neurological Disease
    Cyclobenzaprine-d3 (MK130-d3) hydrochloride is the deuterium labeled Cyclobenzaprine hydrochloride. Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant.
  • HY-106147B
    Frakefamide TFA

    Opioid Receptor Neurological Disease
    Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.
  • HY-150036
    Anthramycin

    Antibiotic Cholecystokinin Receptor Cancer
    Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice.
  • HY-B1111S1
    Amitraz-d3

    BTS-27419-d3

    Adrenergic Receptor Monoamine Oxidase Parasite Infection Endocrinology
    Amitraz-d3 is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.
  • HY-119974
    Caracemide

    NSC-253272

    DNA/RNA Synthesis Bacterial Cancer Infection
    Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity.
  • HY-B1331S
    Cyromazine-d4

    Endogenous Metabolite Neurological Disease
    Cyromazine-d4 is the deuterium labeled Cyromazine. Cyromazine is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects.
  • HY-P1132
    Galanin (1-29)(rat, mouse)

    Neuropeptide Y Receptor Neurological Disease
    Galanin (1-29)(rat, mouse) is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3 respectively. Anticonvulsant effect.
  • HY-101299A
    Dihydrexidine

    DAR-0100

    Dopamine Receptor Neurological Disease
    Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC50 of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity. Dihydrexidine can stimulate YAP phosphorylation.
  • HY-146404
    T761-0184

    nAChR Neurological Disease
    T761-0184 is a potent α7 nicotinic receptor (nAChR) antagonist.
  • HY-101299B
    Dihydrexidine hydrochloride

    DAR-0100 hydrochloride

    Dopamine Receptor Neurological Disease
    Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity. Dihydrexidine hydrochloride can stimulate YAP phosphorylation.
  • HY-151208
    MAO-B-IN-16

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC50 of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease.
  • HY-122150
    AMPA receptor modulator-3

    iGluR Neurological Disease
    AMPA receptor modulator-3 is an allosteric AMPA receptor modulator (EC50: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory.
  • HY-107790
    5-Methoxyflavone

    DNA/RNA Synthesis Neurological Disease
    5-Methoxyflavone, belonged to Flavonoid family, is a DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity. possess central nervous system (CNS) depressant effect mediated through the ionotropic GABAA receptors.
  • HY-108335
    Sipatrigine

    619C89; BW 619C89

    Sodium Channel Calcium Channel Neurological Disease
    Sipatrigine (619C89), a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has the potential in the study for focal cerebral ischemia and stroke.
  • HY-N1501
    Beta-asarone

    Others Inflammation/Immunology Neurological Disease
    Beta-asarone is a major ingredient of Acorus tatarinowii Schott, penetrates blood brain barrier, with the properties of immunosuppression, central nervous system inhibition, sedation, and hypothermy. Beta-asarone protects against Parkinson’s disease.
  • HY-15731
    Estetrol

    Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.
  • HY-N0746
    Oxysophocarpine

    Others Cancer
    Oxysophocarpine is an alkaloid extracted from Siphocampylus verticillatus. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems. Oxysophocarpine inhibits the growth and metastasis of  oral squamous cell carcinoma (OSCC).
  • HY-B1272A
    Desipramine

    Adrenergic Receptor Neurological Disease
    Desipramine is a tricyclic psychotic compound, possessing antidepressant activity. Desipramine inhibits the norepinephrine reuptake receptor in the central nervous system and reduces the sleep-related loss of genioglossus activity, can be used to research the improvement of pharyngeal collapsibility.
  • HY-B0406
    Bethanechol

    Carbamyl-β-methylcholine

    mAChR Neurological Disease
    Bethanechol (Carbamyl-β-methylcholine), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system.
  • HY-B0406A
    Bethanechol chloride

    Carbamyl-β-methylcholine chloride

    mAChR Neurological Disease
    Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system.
  • HY-B0225B
    Methyldopa hydrate

    L-(-)-α-Methyldopa hydrate; MK-351 hydrate

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa hydrate (L-(-)-α-Methyldopa hydrate), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrate is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-B0225A
    Methyldopa hydrochloride

    L-(-)-α-Methyldopa hydrochloride; MK-351 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-N2072
    Transcrocetin

    trans-Crocetin

    iGluR Endogenous Metabolite Cancer
    Transcrocetin (trans-Crocetin), extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity. Transcrocetin (trans-Crocetin) is capable of crossing the blood-brain barrier and reach the central nervous system (CNS).
  • HY-B0225
    Methyldopa

    L-(-)-α-Methyldopa; MK-351

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Methyldopa (L-(-)-α-Methyldopa), a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-116819
    VU0453379

    GCGR Metabolic Disease
    VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM.
  • HY-B0770
    Artemotil

    β-Arteether; (+)-Arteether; Arteether

    Parasite Infection Cancer
    Artemotil (β-Arteether) has antimalarial activity for the treatment of chloroquine-resistant Plasmodium falciparum malaria with an IC50 of 1.61 nM. Artemotil also has central nervous system (CNS) neurotoxicity and anorectic toxicity in rats, dogs and monkeys.
  • HY-N0035
    Arctigenin

    (-)-Arctigenin

    MMP Influenza Virus Autophagy Apoptosis Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
  • HY-P99216
    Ponezumab

    PF-04360365; RN 1219

    EGFR Neurological Disease
    Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.
  • HY-B1331S1
    Cyromazine-13C3

    Cyromazin-13C3; CGA-72662-13C3

    Endogenous Metabolite Neurological Disease
    Cyromazine-13C3 is the 13C3 labeled Cyromazine. Cyromazine is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects.
  • HY-107654S
    Muscarine-d9 iodide

    (+)-Muscarine-d9 iodide

    mAChR Neurological Disease
    Muscarine-d9 iodide ((+)-Muscarine-d9 iodide) is the deuterium labeled Muscarine iodide. Muscarine ((+)-Muscarine) iodide is a toxin that can stimulate the parasympathetic nervous system. Muscarine iodide is a prototype muscarinic acetylcholine receptor agonist.
  • HY-119078
    VU0080241

    mGluR Neurological Disease
    VU0080241 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 4 (mGluR4), with an EC50 of 4.6 μM.
  • HY-103463
    SA57

    FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
  • HY-144116
    A1AR antagonist 2

    Adenosine Receptor Neurological Disease
    A1AR antagonist 2 (compound 18h) is a potent A1 adenosine receptor (AR) antagonist with Kis of 1.49, 10.2, and 50.1 nM for hA1, hA2A and hA2B, respectively.
  • HY-144115
    A1AR antagonist 1

    Adenosine Receptor Neurological Disease
    A1AR antagonist 1 (compound 18g) is a potent A1 adenosine receptor (AR) antagonist with Kis of 2.08, 6.91, and 31.2 nM for hA1, hA2A and hA2B, respectively.
  • HY-147657
    GABAA receptor modulator-2

    GABA Receptor Neurological Disease
    GABAA receptor modulator-2 (Compound 20) is selective, orally active α5-GABAAR negative allosteric modulator (NAM) with a Ki of 4.1 nM. GABAA receptor modulator-2 shows high-metabolic stability and good CNS safety.
  • HY-110285
    ML382

    Others Neurological Disease
    ML382 is a potent and selective MRGPRX1 (Mas-related G protein-coupled receptor X1, MrgX1) positive allosteric modulator, with an EC50 of 190 nM.
  • HY-129586
    AT-007

    Aldose Reductase Metabolic Disease
    AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
  • HY-14450
    JNJ-31020028

    Neuropeptide Y Receptor Neurological Disease Endocrinology
    JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease.
  • HY-B1111S
    Amitraz-d6

    BTS-27419-d6

    Adrenergic Receptor Monoamine Oxidase Parasite Infection Endocrinology
    Amitraz-d6 (BTS-27419-d6) is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.
  • HY-112076
    Atropine methyl bromide

    Methylatropine bromide

    mAChR Neurological Disease
    Atropine methyl bromide, a muscarinic receptor (mAChR) antagonist, is a quaternary ammonium salt of atropine and a mydriatic for dilation of the pupil during ophthalmic examination. It is introduced for relieving pyloric spasm in infants for its highly polar nature. It penetrates less readily into the central nervous system than atropine.
  • HY-N0229S13
    L-Alanine-d7

    L-2-Aminopropionic acid-d7

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-d7 (L-2-Aminopropionic acid-d7) is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-N0229S3
    L-Alanine-d4

    L-2-Aminopropionic acid-d4

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-d4 (L-2-Aminopropionic acid-d4) is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-N0229S12
    L-Alanine-d3

    L-2-Aminopropionic acid-d3

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-d3 (L-2-Aminopropionic acid-d3) is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-15344A
    (S,S)-BD-AcAc 2

    (S,S)-Ketone Ester

    Others Neurological Disease
    (S,S)-BD-AcAc 2 ((S,S)-Ketone Ester) is a (S,S)-enantiomer of BD-AcAc 2. BD-AcAc 2 elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures.
  • HY-13204
    Biperiden hydrochloride

    KL 373 hydrochloride

    mAChR Neurological Disease
    Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden hydrochloride has the potential for the research of Parkinson's disease and other related psychiatric disorders.
  • HY-B0315S
    Vitamin B12-13C7

    Endogenous Metabolite Metabolic Disease
    Vitamin B12-13C7 is the 13C-labeled Vitamin B12. Vitamin B12 is a vitamin. Vitamin B12 plays a key role in the normal functioning of the brain and nervous system, and for the formation of blood.
  • HY-13204A
    Biperiden

    KL 373

    mAChR Neurological Disease
    Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders.
  • HY-150640
    Rho-Kinase-IN-2

    ROCK Neurological Disease
    Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research.
  • HY-B0725A
    Doxepin

    mTOR PI3K Akt Neurological Disease
    Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress.
  • HY-N0229S15
    L-Alanine-13C2,15N

    L-2-Aminopropionic acid-13C2,15N

    Endogenous Metabolite
    L-Alanine-13C2,15N is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-18750
    Zorifertinib

    AZD3759

    EGFR Cancer
    Zorifertinib (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFR wt, EGFR L858R, and EGFR exon 19Del, respectively.
  • HY-B1837A
    β-Cyfluthrin

    beta-Cyfluthrin

    Calcium Channel Neurological Disease
    β-Cyfluthrin (beta-Cyfluthrin) is a type II synthetic pyrethroid and also an active ingredient of many insecticide products used for pestsin agriculture. β-Cyfluthrin is a neurotoxicant and affects calcium concentration in nervous tissue by inhibiting Ca 2+ ATPase involved in calcium transport.
  • HY-N0443
    N-Methylcytisine

    Caulophylline

    nAChR Inflammation/Immunology
    N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities. N-methylcytisine is a selective ligand of nicotinic receptors of acetylcholine in the central nervous system and has a high affinity (Kd = 50 nM) to nicotinic acetylcholine receptors (nAChR) from squid optical ganglia.
  • HY-15731S
    Estetrol-d4

    Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Estetrol-d4 is the deuterium labeled Estetrol. Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.
  • HY-Y1250S5
    Fmoc-Gly-OH-13C2

    Endogenous Metabolite Inflammation/Immunology
    Fmoc-Gly-OH-13C2 is a 13C-labeled Xanthine. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation[1][2][3].
  • HY-B0225AS
    Methyldopa-d3 hydrochloride

    L-(-)-α-Methyldopa-d3 hydrochloride; MK-351-d3 hydrochloride

    Adrenergic Receptor Endogenous Metabolite Cardiovascular Disease Endocrinology
    Methyldopa-d3 (hydrochloride) is deuterium labeled Methyldopa (hydrochloride). Methyldopa hydrochloride (L-(-)-α-Methyldopa hydrochloride) hydrochloride, a potent antihyoertensive agent, is an alpha-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopa hydrochloride is a prodrug and is metabolized (α-Methylepinephrine) in the central nervous system.
  • HY-79128S
    Fmoc-L-Lys (Boc)-OH-15N2

    Endogenous Metabolite Inflammation/Immunology
    Fmoc-L-Lys (Boc)-OH-15N2 is a 15N-labeled Xanthine. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation[1][2][3].
  • HY-B0824
    Bifenthrin

    Sodium Channel Neurological Disease
    Bifenthrin is a synthetic pyrethroid insecticide that prolongs opening of sodium channels resulting in membrane depolarization and conductance block in the insect nervous system. Bifenthrin is effective against A. gambiae and C. quinquefasciatus mosquitos (LD50s = 0.15 and 0.16 ng/mg, respectively) and increases O. insidiosus mortality in treated corn and sorghum plants.
  • HY-N2511
    Trimyristin

    Cholinesterase (ChE) Phosphatase Endogenous Metabolite Metabolic Disease
    Trimyristin, an active molluscicidal component of Myristica fragrans Houtt, significantly inhibits acetylcholinesterase (AChE), acid and alkaline phosphatase (ACP/ALP) activities in the nervous tissue of Lymnaea acuminata. IC50s of Trimyristin against AChE, ACP, and ALP are 0.11, 0.16 and 0.18 mM, respectively.
  • HY-138800
    Spinosad

    nAChR Neurological Disease
    Spinosad, a mixture of spinosyns A and D known as fermentation products of a soil actinomycete (Saccharopolyspora spinosa), is a biological neurotoxic insecticide with a broader action spectrum. Spinosad targets the nicotinic acetylcholine receptor (nAChRs) of the insect nervous system. Spinosad has an excellent environmental and mammalian toxicological profile. Larvicidal activity.
  • HY-N2368A
    Arecaidine hydrochloride

    GABA Receptor Neurological Disease
    Arecaidine hydrochloride, a pyridine alkaloid, is a potent GABA uptake inhibitor. Arecaidine hydrochloride is a substrate of H +-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits L-proline uptake.
  • HY-N2368
    Arecaidine

    GABA Receptor Neurological Disease
    Arecaidine, a pyridine alkaloid, is a potent GABA uptake inhibitor. Arecaidine is a substrate of H +-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits L-proline uptake.
  • HY-149014
    OX2R-IN-1

    Orexin Receptor (OX Receptor) Neurological Disease
    OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life.
  • HY-N2004
    Isoborneol

    (±)-Isoborneol

    HSV Infection Neurological Disease
    Isoborneol ((±)-Isoborneol) is a monoterpenoid alcohol present in the essential oils of numerous medicinal plants and has antioxidant and antiviral properties. Isoborneol is a potent inhibitor of herpes simplex virus type 1 (HSV-1).
  • HY-103354
    Proglumide sodium

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities.
  • HY-P1333
    Dynorphin A

    Opioid Receptor Apoptosis Caspase Endogenous Metabolite Neurological Disease
    Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease.
  • HY-B0836
    λ-Cyhalothrin

    Parasite Sodium Channel Infection Endocrinology Neurological Disease
    λ-Cyhalothrin is a high efficiency, broad-spectrum type II synthetic pyrethroid insecticide containing α-cyano group. λ-Cyhalothrin is used to control a wide range of pests in a variety of applications. λ-Cyhalothrin is a neurotoxin that targets sodium channels in the membranes of neurons in the central nervous system.
  • HY-B1330
    Proglumide

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.
  • HY-N0229S7
    L-Alanine-2-13C

    L-2-Aminopropionic acid-2-13C

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-2-13C (L-2-Aminopropionic acid-2-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-N0229S6
    L-Alanine-3-13C

    L-2-Aminopropionic acid-3-13C

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-3-13C (L-2-Aminopropionic acid-3-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-113498
    Sphingomyelin

    Endogenous Metabolite Metabolic Disease Inflammation/Immunology Neurological Disease
    Sphingomyelin is a eukaryotic sphingolipid and one of the major constituents of cell membranes and particularly abundant in the myelin sheath that surrounds neuronal axons. Sphingomyelin plays an important role in cell processes, the regulation of inflammatory responses, and signal transduction. Sphingomyelin metabolism is associated with various central nervous system diseases and Niemann–Pick disease.
  • HY-N0229S1
    L-Alanine-1-13C

    L-2-Aminopropionic acid-1-13C

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-1-13C (L-2-Aminopropionic acid-1-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-B0406AS
    Bethanechol-d6 chloride

    Carbamyl-β-methylcholine-d6 chloride

    mAChR Neurological Disease
    Bethanechol-d6 (Carbamyl-β-methylcholine-d6) chloride is the deuterium labeled Bethanechol chloride. Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system.
  • HY-17552
    sn-Glycero-3-phosphocholine

    Choline Alfoscerate; Alpha-GPC; L-α-GPC

    Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia.
  • HY-N0229S2
    L-Alanine-15N

    L-2-Aminopropionic acid-15N

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-15N (L-2-Aminopropionic acid-15N) is the 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-109189
    Rezivertinib

    BPI-7711

    EGFR Cancer
    Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity.
  • HY-14951
    Firategrast

    SB 683699

    Integrin Neurological Disease
    Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
  • HY-N0229S8
    L-Alanine-13C3

    L-2-Aminopropionic acid-13C3

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-13C3 (L-2-Aminopropionic acid-13C3) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-103354A
    Proglumide hemicalcium

    Cholecystokinin Receptor Cancer Endocrinology Neurological Disease
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities.
  • HY-13204B
    Biperiden lactate

    KL 373 lactate

    mAChR Neurological Disease
    Biperiden (KL 373) lactate is an orally active non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors. Biperiden (KL 373) lactate inhibits acetylcholine and enhances dopamine signaling in the central nervous system. Biperiden (KL 373) lactate has the potential for the research of Parkinson's disease and other related psychiatric disorders.
  • HY-P1333A
    Dynorphin A TFA

    Opioid Receptor Apoptosis Caspase Endogenous Metabolite Neurological Disease
    Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease.
  • HY-N0229S9
    L-Alanine-13C2

    L-2-Aminopropionic acid-13C2

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-13C2 (L-2-Aminopropionic acid-13C2) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-141140
    5-Ethynyluridine

    5-EU

    Others Others
    5-Ethynyluridine (5-EU) is a potent cell-permeable nucleoside can be used to label newly synthesized RNA. 5-Ethynyluridine can be used for isolation and sequencing of nascent RNA from neuronal populations in vivo. 5-Ethynyluridine can be used to identify changes in transcription in vivo in nervous system disease models.
  • HY-109192
    Tolebrutinib

    SAR442168; PRN2246

    Btk Neurological Disease
    Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS).
  • HY-137499
    NT1-O12B

    Endogenous Metabolite Neurological Disease
    NT1-O12B, an endogenous chemical and a neurotransmitter-derived lipidoid (NT-lipidoid), is an effective carrier for enhanced brain delivery of several blood-brain barrier (BBB)-impermeable cargos. Doping NT1-O12B into BBB-impermeable lipid nanoparticles (LNPs) gives the LNPs the ability to cross the BBB. NT-lipidoids formulation not only facilitate cargo crossing of the BBB, but also delivery of the cargo into neuronal cells for functional gene silencing or gene recombination.
  • HY-Y0123
    DL-Tyrosine

    Others Neurological Disease
    DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine).
  • HY-14905
    Uridine triacetate

    Tri-O-acetyl uridine

    Others Neurological Disease
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active prodrug of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS).
  • HY-N2511S
    Trimyristin--d15

    Cholinesterase (ChE) Phosphatase Endogenous Metabolite
    Trimyristin--d15 is the deuterium labeled Trimyristin. Trimyristin, an active molluscicidal component of Myristica fragrans Houtt, significantly inhibits acetylcholinesterase (AChE), acid and alkaline phosphatase (ACP/ALP) activities in the nervous tissue of Lymnaea acuminata. IC50s of Trimyristin against AChE, ACP, and ALP are 0.11, 0.16 and 0.18 mM, respectively.
  • HY-N0229S4
    L-Alanine-13C,d1

    L-2-Aminopropionic acid-13C,d1

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-13C,d1 (L-2-Aminopropionic acid-13C,d1) is the 13C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-13011
    Alectinib

    CH5424802; RO5424802; AF802

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-N0229S14
    L-Alanine-15N,d4

    L-2-Aminopropionic acid-15N,d4

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-15N,d4 (L-2-Aminopropionic acid-15N,d4) is the deuterium and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-13011A
    Alectinib Hydrochloride

    CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-125021
    2BAct

    Eukaryotic Initiation Factor (eIF) Neurological Disease
    2BAct is a highly selective, and orally active eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct is able to penetrate the central nervous system (CNS). 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB (HY-12495).
  • HY-P1317
    Nociceptin (1-13), amide

    Opioid Receptor Neurological Disease
    Nociceptin (1-13), amide is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.
  • HY-N2252
    Licarin A

    (+)-Licarin A

    TNF Receptor Prostaglandin Receptor COX Metabolic Disease Inflammation/Immunology Neurological Disease
    Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression.
  • HY-148137
    CB1 agonist 1

    Others Neurological Disease
    CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders.
  • HY-P1317A
    Nociceptin (1-13), amide TFA

    Opioid Receptor Neurological Disease
    Nociceptin (1-13), amide TFA is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.
  • HY-13011S1
    Alectinib-d6

    CH5424802-d6; RO5424802-d6; AF802-d6

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib-d6 is deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-N0229S11
    L-Alanine-1-13C,15N

    L-2-Aminopropionic acid-1-13C,15N

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-1-13C,15N (L-2-Aminopropionic acid-1-13C,15N) is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-N0229S10
    L-Alanine-13C3,15N

    L-2-Aminopropionic acid-13C3,15N

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-13C3,15N (L-2-Aminopropionic acid-13C3,15N) is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-W062904
    Laquinimod sodium

    ABR-215062 sodium

    NF-κB Apoptosis Inflammation/Immunology Neurological Disease
    Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
  • HY-106901AS
    Asoxime-d4 dichloride

    HI-6-d4

    nAChR Neurological Disease
    Asoxime-d4 dichloride (HI-6-d4) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system.
  • HY-13010
    Laquinimod

    ABR-215062

    NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
  • HY-N0229S
    L-Alanine-2-13C,15N

    L-2-Aminopropionic acid-2-13C,15N

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-2-13C,15N (L-2-Aminopropionic acid-2-13C,15N) is the 13C-labeled and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-144604
    FPR2 agonist 2

    Others Infection Neurological Disease
    FPR2 agonist 2 is a potent and permeates the blood−brain barrier FPR2 agonist with an EC50 of 0.13 µM, 1.1 µM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity.
  • HY-11052A
    Trap-101 hydrochloride

    Opioid Receptor Neurological Disease
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ 35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases.
  • HY-N0229S5
    L-Alanine-13C3,15N,d4

    L-2-Aminopropionic acid-13C3,15N,d4

    Endogenous Metabolite Metabolic Disease Neurological Disease
    L-Alanine-13C3,15N,d4 (L-2-Aminopropionic acid-13C3,15N,d4) is the deuterium, 13C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
  • HY-105231
    Bryostatin 1

    PKC HIV Cancer Infection Inflammation/Immunology Neurological Disease
    Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties.
  • HY-117482
    BPN-15606

    γ-secretase Neurological Disease
    BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance.
  • HY-13011S
    Alectinib-d8

    CH5424802-d8; RO5424802-d8; AF802-d8

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib-d8 (CH5424802-d8) is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-107782
    Picrotin

    Others Neurological Disease
    Picrotin is an active compound, also is one of the composition of picrotoxin (an antagonist of GABAA receptors (GABAARs) and glycine receptors (GlyRs)). Picrotin has sensitivity for GlyRs/b> with IC50 values range from 5.2 μM to 106 μM. Picrotin can be used for the research of neurotransmission.
  • HY-117482A
    BPN-15606 besylate

    γ-secretase Neurological Disease
    BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance.
  • HY-17552S
    sn-Glycero-3-phosphocholine-d9

    Choline Alfoscerate-d9; Alpha-GPC-d9; L-α-GPC-d9

    Cholinesterase (ChE) Endogenous Metabolite Neurological Disease
    sn-Glycero-3-phosphocholine-d9 (Choline Alfoscerate-d9) is the deuterium labeled sn-Glycero-3-phosphocholine. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia.
  • HY-B2152
    Hemicholinium 3

    Hemicholinium dibromide

    Cholinesterase (ChE) Neurological Disease
    Hemicholinium 3 is a competitive inhibitor of the high affinity choline transporter (HACU) with a Ki value of 25 nM. Hemicholinium 3, a neuromuscular blocking agent which inhibits the synthesis and the release of acetylcholine (ACh). Hemicholinium 3 inhibits the Epibatidine-evoked contraction and [ 3H]acetylcholine release with IC50s of 897 nM and 693 nM, respectively.
  • HY-W014700
    Glycyl-L-glutamic acid

    Cholinesterase (ChE) Neurological Disease
    Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration.
  • HY-B0725
    Doxepin Hydrochloride

    Histamine Receptor Cytochrome P450 Neurological Disease
    Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2. Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant.
    . Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system.
    . Doxepin has also been proposed as a protective factor against oxidative stress.
    .
  • HY-14151
    Prucalopride

    5-HT Receptor Neurological Disease Cancer
    Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer.
  • HY-133910
    Lu AE98134

    Sodium Channel Neurological Disease
    Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al.
  • HY-122026
    PF-04802367

    PF-367

    GSK-3 Neurological Disease
    PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively.
  • HY-10968
    CYM5442

    LPL Receptor Neurological Disease
    CYM5442 is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS).
  • HY-10968A
    CYM5442 hydrochloride

    LPL Receptor Neurological Disease
    CYM5442 hydrochloride is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 hydrochloride is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 hydrochloride activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 hydrochloride can easily penetrate the central nervous system (CNS).
  • HY-151094
    FTEAA

    Monoamine Oxidase Neurological Disease
    FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research.
  • HY-P1944A
    Apelin-13 TFA

    Apelin Receptor (APJ) Metabolic Disease Cardiovascular Disease
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.
  • HY-P0244A
    Dermorphin TFA

    Opioid Receptor Neurological Disease
    Dermorphin TFA is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain.
  • HY-P0244
    Dermorphin

    Opioid Receptor Neurological Disease
    Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain.
  • HY-13948
    Angiotensin II human

    Angiotensin II; Ang II; DRVYIHPF

    Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
  • HY-13948B
    Angiotensin II human TFA

    Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA

    Angiotensin Receptor Apoptosis Cancer Endocrinology Cardiovascular Disease
    Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
  • HY-13948A
    Angiotensin II human acetate

    Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate

    Angiotensin Receptor Apoptosis Cancer Endocrinology Cardiovascular Disease
    Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
  • HY-147409
    Ulecaciclib

    CDK Cancer
    Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics.
  • HY-147377
    N-Salicyloyltryptamine

    Calcium Channel ERK Potassium Channel Guanylate Cyclase NF-κB Inflammation/Immunology Neurological Disease
    N-Salicyloyltryptamine acts on voltage-dependent Na +, Ca 2+, and K + ion channels inhibitor. N-Salicyloyltryptamine inhibits K + currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect -.